SlideShare una empresa de Scribd logo
1 de 16
Drugs Affecting
The Autonomic Nervous System(ANS)
β-Adrenergic Blockers
ANS Pharmacology
Lecture 7
Dr. Hiwa K. Saaed
College of Pharmacy/University of Sulaimani
2017-2018
β-Adrenergic Blockers
• β-Blockers are effective in treating:
• angina,
• cardiac arrhythmias,
• myocardial infarction,
• congestive heart failure,
• hyperthyroidism,
• and glaucoma,
• as well as serving in the prophylaxis of migraine headaches.
• Note: The names of all β-blockers end in “olol” except for labetalol and carvedilol.
• All are competitive antagonists
• Propranolol is prototype
• Although all β-blockers lower blood pressure in hypertension, they do not induce
postural hypotension!? because the α-adrenoceptors remain functional.
A. Classification and Mechanisms
• Selectivity (β1>β2)
• Partial agonist activity (Intrinsic Sympathomimetic Activity “ISA”)
• Lipid solubility (CNS effect)
• Membrane stabilizing activity (MSA)(local anesthetic action)
• Capacity to block alpha adrenoceptors.
• K+ channel blockade (sotalol)
1. Selectivity (β1>β2)
β1 selective (cardioselective)
• Atenolol
• Acebutolol
• Bisoprolol
• Esmolol (short t1/2)
• Metoplrolol
Advantage: HTN with asthma,
peripheral vascular disease (coldness
of extremities), NIDDM
Selective β2
• Butoxamine (experimental)
Nonselective (β1 & β2)
• Nadolol
• Propranolol
• Timolol
2, Combined (α & β): peripheral vasodilation
Labetalol & Carvedilol
• Useful in Rx HTN patients for whom increased Peripheral resistance is
undesirable (elderly or black)
• Labetalol in Rx preeclampsia, pheochromocytoma
• They do not alter serum lipid or blood glucose levels
• Carvedilol also decreasees lipid peroxidation and vascular wall thickening
(benefit in heart failure)
3. Partial agonist activity ISA
Pindolol, Acebutolol & Labetalol
less bradycardia & diminished effect on CO,
less disturbances of lipid and carbohydrate metabolism
Advantages:
• HTN with asthma,
• HTN with moderate bradycardia
• HTN+DM
4. Local anesthetic activity (membrane-stabilizing activity):
Is a disadvantage when used topically in the eye because it decreases protective
reflexes and increases the risk of corneal ulceration
Timolol, atenolol, carvedilol & nadolol: no Local anesthetic activity
5. Lipid solubility
Lipid soluble
• Propranolol. Timolol. Pindolol
Metoprolol. Labetalol
Pharmacokinetic properties
• Highly metabolized
• Large Vd
• CNS penetration
• Shorter t1/2
WATER SOLUBLE
• Acebutolol, Atenolol, Esmolol,
Nadolol
Pharmacokinetic properties
• Excreted unchanged by kidney
• Less 1st pass effect
• Small Vd
• Longer t1/2 except esmolol
6. K+ channel blockade: sotalol
• Sotalol is a nonselective β receptor antagonists,
• that lack Local Anesthetic action
• but has marked class III antiarrhythmia effect reflecting k+ channel
blockade
B. Pharmacological Effects and Clinical Uses
1. CVS:
A. Heart: both
• decreased HR, force of contraction (–ve inotropic & chronotropic effect)
• decreased A-V conduction, ↑PR interval
• Decrease CO, work & O2 consumption
Rx: Angina and Supraventricular tachycardia
B. Vascular system: prevent β2 mediated vasodilation→ reduction in CO
(because of cardiac effect) → decrease BP → reflex vasoconstriction.
On balance there is gradual reduction of both systolic and diastolic BP
2. Respiratory: bronchoconstriction; contraindicated in asthma
3. Eye: reduce IOP especially in Glaucomatous eyes decrease aqueous humor
production
4. metabolic and endocrine effects:
A. Increased Na+ retention, how?
• Reduced BP causes a decrease in renal perfusion, resulting in an increase in Na+
retention and ↑plasma volume → In some cases, ↑BP.
• For these patients, β-blockers are often combined with a diuretic to prevent Na+
retention.
• Also by inhibiting β receptors, renin production is also prevented, contributing to
Na+ retention.
B. Pharmacological Effects and Clinical Uses
B. inhibit lipolysis: ↑ plasma VLDL, ↓ HDL,─LDL
↓ HDL/LDL ratio→ coronary heart disease
C. partially inhibit glycogenolysis and decrease glucagon secretion
Great caution in IDDM (Type 1)?
Because pronounce hypoglycemia may occur after insulin injection, β blockers also
attenuate the normal physiologic response to hypoglycemia, furthermore they
mask signs of hypoglycemia; tremor, palpitation..
4. metabolic and endocrine effects:
B. Pharmacological Effects and Clinical Uses
Cardiovascular and ophthalmic applications are extremly important
A. CVS:
-angina pectoris ↓cardiac work & O2 demand,
-Chronic hypertension, ↓CO, ↓ TPR, inhibition of renin release
NB: β blockers are not used for acute or emergency Rx of HTN,? may increase diastolic pressure
Labetalol is effective in emergency HTN
-Arrhythmia (supraventricular tachycardias),
-prophylaxis after MI:
1) early use within 6-12 hrs for 3-4 wks
2) Late use within 4 days- 4 wks after onset of infarction and continued for at least 2 years useful for secondary
prevention from another MI
- congestive heart failure*
B. Eye: Glaucoma: reduce aqueous humor secretion (timolol)
C. Endocrine use: Thyroid storm, thyrotoxicosis: propranolol
D. CNS: propranolol
1. Anxiety with somatic symptoms
2. Migraine headache prophylaxis:
3. Famillial tremor, other types of tremor, “stage fright”:
4. Alcohol, opioids acute withdrawal symptoms
B. Pharmacological Effects and Clinical Uses
C. Adverse effects
• CVS: bradycardia, A-V blockade, CHF
• Arrhythmias: never stop Rx with β blockers suddenly
• Bronchoconstriction: Patients with airway disease: asthmatic attack
• Sexual dysfunction?? Independent of β blockade
• CNS effects: sedation, fatigue, sleep alterations
L7 ans pharmacology 17 18

Más contenido relacionado

La actualidad más candente

Introduction to Autonomic Nervous system
Introduction to Autonomic Nervous systemIntroduction to Autonomic Nervous system
Introduction to Autonomic Nervous systemNaser Tadvi
 
Club Drugs Powerpoint
Club Drugs PowerpointClub Drugs Powerpoint
Club Drugs Powerpointgsagan
 
Steroids medicinal chemistry pharm d 3rd year
Steroids medicinal chemistry pharm d 3rd yearSteroids medicinal chemistry pharm d 3rd year
Steroids medicinal chemistry pharm d 3rd yearRaghuram Vallabhaneni
 
ORGANSATION & FUNCTIONS OF ANS
ORGANSATION & FUNCTIONS OF ANSORGANSATION & FUNCTIONS OF ANS
ORGANSATION & FUNCTIONS OF ANSHeena Parveen
 
Drugs Used in Hypertension
Drugs Used in HypertensionDrugs Used in Hypertension
Drugs Used in HypertensionUsmanKhalid135
 
Fibrates - class, effects, side effects, drugs interactions, main indications...
Fibrates - class, effects, side effects, drugs interactions, main indications...Fibrates - class, effects, side effects, drugs interactions, main indications...
Fibrates - class, effects, side effects, drugs interactions, main indications...OlgaGoryacheva4
 
6.adrenergic blockers
6.adrenergic blockers6.adrenergic blockers
6.adrenergic blockersLama K Banna
 
Sympathomimetic System- Pharmacology
Sympathomimetic System- PharmacologySympathomimetic System- Pharmacology
Sympathomimetic System- PharmacologyAdarshPatel73
 
Mechanism of general anaesthesia at molecular level.
Mechanism of general anaesthesia at molecular level.Mechanism of general anaesthesia at molecular level.
Mechanism of general anaesthesia at molecular level.narasimha reddy
 
Adrenergic Antagonist (blockers) Introduction, classification
Adrenergic Antagonist (blockers) Introduction, classificationAdrenergic Antagonist (blockers) Introduction, classification
Adrenergic Antagonist (blockers) Introduction, classificationDrParthiban1
 
Introduction to autonomic nervous system
Introduction to autonomic nervous systemIntroduction to autonomic nervous system
Introduction to autonomic nervous systemDr.Bhargav Purohit
 

La actualidad más candente (20)

Introduction to Autonomic Nervous system
Introduction to Autonomic Nervous systemIntroduction to Autonomic Nervous system
Introduction to Autonomic Nervous system
 
Club Drugs Powerpoint
Club Drugs PowerpointClub Drugs Powerpoint
Club Drugs Powerpoint
 
Cardiac glycosides
Cardiac glycosidesCardiac glycosides
Cardiac glycosides
 
cns depressants
cns depressantscns depressants
cns depressants
 
Calcium channel blockers
Calcium channel blockersCalcium channel blockers
Calcium channel blockers
 
Steroids medicinal chemistry pharm d 3rd year
Steroids medicinal chemistry pharm d 3rd yearSteroids medicinal chemistry pharm d 3rd year
Steroids medicinal chemistry pharm d 3rd year
 
ANTI-ASTHMATICS
ANTI-ASTHMATICSANTI-ASTHMATICS
ANTI-ASTHMATICS
 
Class antianginal
Class  antianginalClass  antianginal
Class antianginal
 
ORGANSATION & FUNCTIONS OF ANS
ORGANSATION & FUNCTIONS OF ANSORGANSATION & FUNCTIONS OF ANS
ORGANSATION & FUNCTIONS OF ANS
 
Drugs Used in Hypertension
Drugs Used in HypertensionDrugs Used in Hypertension
Drugs Used in Hypertension
 
Fibrates - class, effects, side effects, drugs interactions, main indications...
Fibrates - class, effects, side effects, drugs interactions, main indications...Fibrates - class, effects, side effects, drugs interactions, main indications...
Fibrates - class, effects, side effects, drugs interactions, main indications...
 
6.adrenergic blockers
6.adrenergic blockers6.adrenergic blockers
6.adrenergic blockers
 
Antidiuretics
AntidiureticsAntidiuretics
Antidiuretics
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Sympathomimetic System- Pharmacology
Sympathomimetic System- PharmacologySympathomimetic System- Pharmacology
Sympathomimetic System- Pharmacology
 
Mechanism of general anaesthesia at molecular level.
Mechanism of general anaesthesia at molecular level.Mechanism of general anaesthesia at molecular level.
Mechanism of general anaesthesia at molecular level.
 
Cvs drugs new
Cvs drugs   newCvs drugs   new
Cvs drugs new
 
Antihypertensive drugs
Antihypertensive drugs  Antihypertensive drugs
Antihypertensive drugs
 
Adrenergic Antagonist (blockers) Introduction, classification
Adrenergic Antagonist (blockers) Introduction, classificationAdrenergic Antagonist (blockers) Introduction, classification
Adrenergic Antagonist (blockers) Introduction, classification
 
Introduction to autonomic nervous system
Introduction to autonomic nervous systemIntroduction to autonomic nervous system
Introduction to autonomic nervous system
 

Similar a L7 ans pharmacology 17 18

Adrenergic drugs β adrenergic blocker
Adrenergic drugs β adrenergic blockerAdrenergic drugs β adrenergic blocker
Adrenergic drugs β adrenergic blockerSubramani Parasuraman
 
Beta blocker dr. kiran..
Beta blocker dr. kiran..Beta blocker dr. kiran..
Beta blocker dr. kiran..Kiran Piparva
 
Beta adrenoceptor blockers
Beta adrenoceptor blockersBeta adrenoceptor blockers
Beta adrenoceptor blockersssaliemma1
 
Antiadrenergic system and drugs
Antiadrenergic system and drugsAntiadrenergic system and drugs
Antiadrenergic system and drugsBikashAdhikari26
 
Medicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxMedicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxSameena Ramzan
 
Beta receptor blockers receptors action moa adr
Beta receptor blockers receptors action moa adrBeta receptor blockers receptors action moa adr
Beta receptor blockers receptors action moa adrvijiarumugamvsvs
 
Noradrenergic transmission
Noradrenergic transmissionNoradrenergic transmission
Noradrenergic transmissionSazan Jamil Ali
 
Beta receptor blockers
Beta receptor blockersBeta receptor blockers
Beta receptor blockersKarthika Raju
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockersMuniSahu
 
BETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMABETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMAshrinathraman
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockersKarun Kumar
 
Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01Dr Ramesh Krishnan
 
Anti adrenergic drugs
Anti adrenergic drugsAnti adrenergic drugs
Anti adrenergic drugsSabaShaikh76
 

Similar a L7 ans pharmacology 17 18 (20)

L8: B-adrenergic blockers
L8: B-adrenergic blockersL8: B-adrenergic blockers
L8: B-adrenergic blockers
 
Beta blocker
Beta blockerBeta blocker
Beta blocker
 
Adrenergic drugs β adrenergic blocker
Adrenergic drugs β adrenergic blockerAdrenergic drugs β adrenergic blocker
Adrenergic drugs β adrenergic blocker
 
Beta blocker dr. kiran..
Beta blocker dr. kiran..Beta blocker dr. kiran..
Beta blocker dr. kiran..
 
Beta adrenoceptor blockers
Beta adrenoceptor blockersBeta adrenoceptor blockers
Beta adrenoceptor blockers
 
Antiadrenergic system and drugs
Antiadrenergic system and drugsAntiadrenergic system and drugs
Antiadrenergic system and drugs
 
Alpha Adrenoceptor Antagonists.ppt
Alpha Adrenoceptor Antagonists.pptAlpha Adrenoceptor Antagonists.ppt
Alpha Adrenoceptor Antagonists.ppt
 
Medicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxMedicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptx
 
Beta receptor blockers receptors action moa adr
Beta receptor blockers receptors action moa adrBeta receptor blockers receptors action moa adr
Beta receptor blockers receptors action moa adr
 
Noradrenergic transmission
Noradrenergic transmissionNoradrenergic transmission
Noradrenergic transmission
 
Adrenal receptors antagonist
Adrenal receptors antagonistAdrenal receptors antagonist
Adrenal receptors antagonist
 
Beta receptor blockers
Beta receptor blockersBeta receptor blockers
Beta receptor blockers
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockers
 
BETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMABETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMA
 
Beta blockers
Beta blockers Beta blockers
Beta blockers
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockers
 
Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01
 
Adrenal receptors antagonist
Adrenal receptors antagonistAdrenal receptors antagonist
Adrenal receptors antagonist
 
Anti adrenergic drugs
Anti adrenergic drugsAnti adrenergic drugs
Anti adrenergic drugs
 
Hypertension II
Hypertension IIHypertension II
Hypertension II
 

Más de College of Pharmacy University of Sulaimani

Más de College of Pharmacy University of Sulaimani (20)

L3 ans pharmacology 2017 2018
L3 ans pharmacology 2017 2018L3 ans pharmacology 2017 2018
L3 ans pharmacology 2017 2018
 
L4 ans pharmacology 17 18
L4 ans pharmacology 17 18L4 ans pharmacology 17 18
L4 ans pharmacology 17 18
 
L6 ans pharmacology 17 18
L6 ans pharmacology 17 18L6 ans pharmacology 17 18
L6 ans pharmacology 17 18
 
L5 ans pharmacology 17 18
L5 ans pharmacology 17 18L5 ans pharmacology 17 18
L5 ans pharmacology 17 18
 
Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16
 
Heart failure
Heart failureHeart failure
Heart failure
 
Diuretics
DiureticsDiuretics
Diuretics
 
Antiarrythmic drugs
Antiarrythmic drugsAntiarrythmic drugs
Antiarrythmic drugs
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
L7
L7L7
L7
 
L2
L2L2
L2
 
L1: Drugs acting on the ANS
L1: Drugs acting on the ANSL1: Drugs acting on the ANS
L1: Drugs acting on the ANS
 
L6: adrenergic neurotransmition/ agonists
L6: adrenergic neurotransmition/ agonistsL6: adrenergic neurotransmition/ agonists
L6: adrenergic neurotransmition/ agonists
 
L5: Adrenergic agonists; sympathomimetics
L5: Adrenergic agonists; sympathomimeticsL5: Adrenergic agonists; sympathomimetics
L5: Adrenergic agonists; sympathomimetics
 
L 4: Cholinergic antagonists
L 4: Cholinergic antagonistsL 4: Cholinergic antagonists
L 4: Cholinergic antagonists
 
L3:cholinomimetics
L3:cholinomimeticsL3:cholinomimetics
L3:cholinomimetics
 
local anesthetics
local anestheticslocal anesthetics
local anesthetics
 
Week 8 helping patients manage therapeutic regimens
Week 8 helping patients manage therapeutic regimensWeek 8 helping patients manage therapeutic regimens
Week 8 helping patients manage therapeutic regimens
 
Week 7 interviewing and assessement
Week 7 interviewing and assessementWeek 7 interviewing and assessement
Week 7 interviewing and assessement
 

Último

Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterMateoGardella
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.MateoGardella
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingTeacherCyreneCayanan
 
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...KokoStevan
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 

Último (20)

Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 

L7 ans pharmacology 17 18

  • 1. Drugs Affecting The Autonomic Nervous System(ANS) β-Adrenergic Blockers ANS Pharmacology Lecture 7 Dr. Hiwa K. Saaed College of Pharmacy/University of Sulaimani 2017-2018
  • 2.
  • 3. β-Adrenergic Blockers • β-Blockers are effective in treating: • angina, • cardiac arrhythmias, • myocardial infarction, • congestive heart failure, • hyperthyroidism, • and glaucoma, • as well as serving in the prophylaxis of migraine headaches. • Note: The names of all β-blockers end in “olol” except for labetalol and carvedilol. • All are competitive antagonists • Propranolol is prototype • Although all β-blockers lower blood pressure in hypertension, they do not induce postural hypotension!? because the α-adrenoceptors remain functional.
  • 4. A. Classification and Mechanisms • Selectivity (β1>β2) • Partial agonist activity (Intrinsic Sympathomimetic Activity “ISA”) • Lipid solubility (CNS effect) • Membrane stabilizing activity (MSA)(local anesthetic action) • Capacity to block alpha adrenoceptors. • K+ channel blockade (sotalol)
  • 5. 1. Selectivity (β1>β2) β1 selective (cardioselective) • Atenolol • Acebutolol • Bisoprolol • Esmolol (short t1/2) • Metoplrolol Advantage: HTN with asthma, peripheral vascular disease (coldness of extremities), NIDDM Selective β2 • Butoxamine (experimental) Nonselective (β1 & β2) • Nadolol • Propranolol • Timolol
  • 6. 2, Combined (α & β): peripheral vasodilation Labetalol & Carvedilol • Useful in Rx HTN patients for whom increased Peripheral resistance is undesirable (elderly or black) • Labetalol in Rx preeclampsia, pheochromocytoma • They do not alter serum lipid or blood glucose levels • Carvedilol also decreasees lipid peroxidation and vascular wall thickening (benefit in heart failure)
  • 7. 3. Partial agonist activity ISA Pindolol, Acebutolol & Labetalol less bradycardia & diminished effect on CO, less disturbances of lipid and carbohydrate metabolism Advantages: • HTN with asthma, • HTN with moderate bradycardia • HTN+DM 4. Local anesthetic activity (membrane-stabilizing activity): Is a disadvantage when used topically in the eye because it decreases protective reflexes and increases the risk of corneal ulceration Timolol, atenolol, carvedilol & nadolol: no Local anesthetic activity
  • 8. 5. Lipid solubility Lipid soluble • Propranolol. Timolol. Pindolol Metoprolol. Labetalol Pharmacokinetic properties • Highly metabolized • Large Vd • CNS penetration • Shorter t1/2 WATER SOLUBLE • Acebutolol, Atenolol, Esmolol, Nadolol Pharmacokinetic properties • Excreted unchanged by kidney • Less 1st pass effect • Small Vd • Longer t1/2 except esmolol
  • 9. 6. K+ channel blockade: sotalol • Sotalol is a nonselective β receptor antagonists, • that lack Local Anesthetic action • but has marked class III antiarrhythmia effect reflecting k+ channel blockade
  • 10. B. Pharmacological Effects and Clinical Uses 1. CVS: A. Heart: both • decreased HR, force of contraction (–ve inotropic & chronotropic effect) • decreased A-V conduction, ↑PR interval • Decrease CO, work & O2 consumption Rx: Angina and Supraventricular tachycardia B. Vascular system: prevent β2 mediated vasodilation→ reduction in CO (because of cardiac effect) → decrease BP → reflex vasoconstriction. On balance there is gradual reduction of both systolic and diastolic BP
  • 11. 2. Respiratory: bronchoconstriction; contraindicated in asthma 3. Eye: reduce IOP especially in Glaucomatous eyes decrease aqueous humor production 4. metabolic and endocrine effects: A. Increased Na+ retention, how? • Reduced BP causes a decrease in renal perfusion, resulting in an increase in Na+ retention and ↑plasma volume → In some cases, ↑BP. • For these patients, β-blockers are often combined with a diuretic to prevent Na+ retention. • Also by inhibiting β receptors, renin production is also prevented, contributing to Na+ retention. B. Pharmacological Effects and Clinical Uses
  • 12. B. inhibit lipolysis: ↑ plasma VLDL, ↓ HDL,─LDL ↓ HDL/LDL ratio→ coronary heart disease C. partially inhibit glycogenolysis and decrease glucagon secretion Great caution in IDDM (Type 1)? Because pronounce hypoglycemia may occur after insulin injection, β blockers also attenuate the normal physiologic response to hypoglycemia, furthermore they mask signs of hypoglycemia; tremor, palpitation.. 4. metabolic and endocrine effects:
  • 13. B. Pharmacological Effects and Clinical Uses Cardiovascular and ophthalmic applications are extremly important A. CVS: -angina pectoris ↓cardiac work & O2 demand, -Chronic hypertension, ↓CO, ↓ TPR, inhibition of renin release NB: β blockers are not used for acute or emergency Rx of HTN,? may increase diastolic pressure Labetalol is effective in emergency HTN -Arrhythmia (supraventricular tachycardias), -prophylaxis after MI: 1) early use within 6-12 hrs for 3-4 wks 2) Late use within 4 days- 4 wks after onset of infarction and continued for at least 2 years useful for secondary prevention from another MI - congestive heart failure*
  • 14. B. Eye: Glaucoma: reduce aqueous humor secretion (timolol) C. Endocrine use: Thyroid storm, thyrotoxicosis: propranolol D. CNS: propranolol 1. Anxiety with somatic symptoms 2. Migraine headache prophylaxis: 3. Famillial tremor, other types of tremor, “stage fright”: 4. Alcohol, opioids acute withdrawal symptoms B. Pharmacological Effects and Clinical Uses
  • 15. C. Adverse effects • CVS: bradycardia, A-V blockade, CHF • Arrhythmias: never stop Rx with β blockers suddenly • Bronchoconstriction: Patients with airway disease: asthmatic attack • Sexual dysfunction?? Independent of β blockade • CNS effects: sedation, fatigue, sleep alterations